|
Drug Information
Pharmacokinetics
| Indication
& Dosage | Action
| Interactions Precautions |
Brands available in Market
It is completely absorbed with an oral bioavaiability of 89%. Plasma binding exceeds 99.5%. Total plasma clearance was 0.42 to 0.48 I/h. Dual excretion was observed in urine and faeces. Food intake had no impact on the pharmacokinetics of the drug.
Meloxicam is a new NSAID of the oxicam class. it differs from other NSAIDS in that it has a greater selective inhibitory activity against the inducible isoform of cyclo oxygenase (COX-2) than against the COX-1, which is associated with gastrointestinal/renal adverse effect and inhibition of platelet aggregation effects of the NSAIDS.
Cimetidine, aluminium/magnesium hydroxide antacid or aspiring: Concomitant use did nt significantly affect the pharmacokinetic profile of meloxicam.
Frusemide or digoxin: Meloxicam did not affect the pharmacokinetics inshort time studies.
Peptic ulcer
Pregnancy: Contraindicated.
Breast Feeding: Contraindicated
Man: Use with caution
